Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-10

Bicara Therapeutics (BCAX)

CEO Claire Mazumdar was paid $927,688 in fiscal year 2025, ↓ down 89.6% from fiscal year 2024 (SEC filing 0001628280-26-027320 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$927,688 ↓
Claire Mazumdar total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Claire Mazumdar (Chief Executive Officer), FY2025 total compensation $927,688 (base salary $625,000) [exec_comp, SEC accession 0001628280-26-027320, filed 2026-04-27]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

BCAX's next annual pay disclosure, estimated April 27, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Claire Mazumdar$625,000$0$0$0$292,188$0$10,500$927,688
Chief Executive Officer
Ryan Cohlhepp588,00010,00000249,900010,500858,400
President and Chief Operating Officer
David Raben525,0005,00000170,62508,539709,164
Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Claire Mazumdar$927,688$8,918,523—↓ −7,990,835
Ryan Cohlhepp858,4004,467,589—↓ −3,609,189
David Raben709,164———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Bicara Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper BCAX reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against BCAX
No companies currently name BCAX as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Claire MazumdarCEO$927,688
Ryan CohlheppPresident$858,400
David RabenChief Medical Officer$709,164
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Carolyn NgIndependent Director—
Christopher BowdenIndependent Director$253,634
Jake SimsonIndependent Director$252,634
Kate HavilandIndependent Director$253,634
Kiran Mazumdar-ShawIndependent Director$252,634
Michael PowellIndependent Director$296,134
Nils LonbergIndependent Director$256,634
Scott RobertsonIndependent Director$263,634
02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Claire MazumdarOption90,9814.1—
Claire MazumdarOption8,3344.1—
Claire MazumdarOption16,2274.44—
Claire MazumdarOption68,9653.79—
Claire MazumdarOption163,0503.79—
Claire MazumdarOption297,5045.45—
Claire MazumdarOption784,6729.24—
Claire MazumdarOption3,1264.1—
Claire MazumdarOption17,7104.1—
Claire MazumdarOption44,6253.79—
Claire MazumdarOption106,2543.79—
Claire MazumdarOption189,3205.45—
Claire MazumdarOption353,2879.24—
David RabenOption66,0043.79—
David RabenOption37,8633.79—
David RabenOption77,0805.45—
David RabenOption148,7539.24—
05

Incentive-plan design — the Compensation Discussion & Analysis

The Company's compensation philosophy is designed to motivate employees to achieve short- and long-term results in the best interests of stockholders, aligning executive interests with stockholders through equity grants that create an ownership culture and promote retention. Compensation is set based on market benchmarks, individual performance, and a desire to maintain a competitive position.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantPearl Meyer
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-09—————
20252025-06-09—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-09—a
20252025-06-09—b

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Michael PowellIndependent$87,500—$208,634——$296,134
Scott RobertsonIndependent55,000—208,634——263,634
Nils LonbergIndependent48,000—208,634——256,634
Christopher BowdenIndependent45,000—208,634——253,634
Kate HavilandIndependent45,000—208,634——253,634
Jake SimsonIndependent44,000—208,634——252,634
Kiran Mazumdar-ShawIndependent44,000—208,634——252,634
Carolyn NgIndependent0—0——0
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$47,492
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 10,000 / 8,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$368,500
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$368,500

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Bicara Therapeutics2025Claire Mazumdar$625,000$0$0$292,188$927,688

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Bicara Therapeutics in fiscal 2025?
As disclosed, Claire Mazumdar (Chief Executive Officer) was the highest-paid executive at Bicara Therapeutics in fiscal 2025, with total compensation of $927,688.
How much does Bicara Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Bicara Therapeutics reported total board compensation of $368,500 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Claire MazumdarDEF 14A2026-04-270001628280-26-027320Section “Executive Compensation”. As printed: 927,688. Filing ↗machine: r2 · c21 · span 297846–297853
2Section 01, Ryan CohlheppDEF 14A2026-04-270001628280-26-027320Section “Executive Compensation”. As printed: 858,400. Filing ↗machine: r4 · c21 · span 301875–301882
3Section 01, David RabenDEF 14A2026-04-270001628280-26-027320Section “Executive Compensation”. As printed: 709,164. Filing ↗machine: r6 · c21 · span 306020–306027
4Section 07, pay ratio10-K2026-03-300001628280-26-022010Section “CEO Pay Ratio”. As printed: —. Filing ↗
5Section 08, Michael PowellDEF 14A2026-04-270001628280-26-027320Section “Director Compensation”. As printed: 296,134. Filing ↗machine: span 252262–252568
6Section 08, Scott RobertsonDEF 14A2026-04-270001628280-26-027320Section “Director Compensation”. As printed: 263,634. Filing ↗machine: span 253930–254236
7Section 08, Nils LonbergDEF 14A2026-04-270001628280-26-027320Section “Director Compensation”. As printed: 256,634. Filing ↗machine: span 247245–247551
8Section 08, Christopher BowdenDEF 14A2026-04-270001628280-26-027320Section “Director Compensation”. As printed: 253,634. Filing ↗machine: span 243855–244187
9Section 08, Kate HavilandDEF 14A2026-04-270001628280-26-027320Section “Director Compensation”. As printed: 253,634. Filing ↗machine: span 245573–245879
10Section 08, Jake SimsonDEF 14A2026-04-270001628280-26-027320Section “Director Compensation”. As printed: 252,634. Filing ↗machine: span 255602–255908
11Section 08, Kiran Mazumdar-ShawDEF 14A2026-04-270001628280-26-027320Section “Director Compensation”. As printed: 252,634. Filing ↗machine: span 248917–249223
12Section 08, Carolyn NgDEF 14A2026-04-270001628280-26-027320Section “Director Compensation”. As printed: 0. Filing ↗
13Section 06, 2026 voteForm 8-K2026-06-100001628280-26-042176Item 5.07 · say-on-pay result. As reported: —. Filing ↗
14Section 06, 2025 voteForm 8-K2025-06-120002023658-25-000082Item 5.07 · say-on-pay result. As reported: —. Filing ↗
15Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
16Section 09b board cost (computed)Computed——Cash 368,500 + equity 0 + all other 0 = 368,500, summed across the director compensation table rows.machine: formula: Σ = 368,500
17Bicara Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-270001628280-26-027320CEO total compensation as printed in Bicara Therapeutics's own proxy. As printed: 927,688. Filing ↗machine: r2 · c21 · span 297846–297853

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.